NCT03994627Approved For Marketing不适用
An Open-Label, Multi-Center Patient Access Program of Olaratumab for the Treatment of Soft Tissue Sarcoma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 87
研究概览
简要总结
The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS).
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Are currently receiving olaratumab and who, in consultation with their treating physician, want to continue their course of therapy.
- •Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.
- •Have given written informed consent.
- •Have an absolute neutrophil count (ANC) ≥1,000/microliter.
- •Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is, <1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.
排除标准
- •Breastfeeding (patients who discontinue breastfeeding would be considered eligible).
研究者
研究点 (87)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisMultiple SclerosisNCT02807285Genentech, Inc.
已完成
2 期
A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell LymphomaLymphoma, Mantle-CellNCT05564052Janssen Research & Development, LLC36
No Longer Available
不适用
A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In IndiaHuman Immunodeficiency Virus (HIV)NCT00992654ViiV Healthcare
Approved For Marketing
不适用
An Expanded Access Program of Emicizumab in Participants With Hemophilia A With InhibitorsHemophilia ANCT03154437Genentech, Inc.
已完成
3 期
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)Crohn's DiseaseNCT00338650Abbott1,000